Arcturus Therapeutics’ Post

Really excited to share with you my first press release in my new role as Infectious Disease Analyst at GlobalData Plc! With GSK halting its Herpes simplex virus (HSV) vaccine development, the spotlight is now on Moderna and BioNTech SE to lead the charge with their promising mRNA-based vaccines. As global cases continue to rise in prevalence, 54 million cases expected by 2029, the potential impact for a successful vaccine is significant. Further insights from GlobalData shortly to follow. Click to read more. #globaldata #mRNA #Vaccines #Pharma #Herpes

GSK and CureVac Restructure Collaboration into New Licensing Agreement to Enhance mRNA DevelopmentGSK plc and CureVac N.V. have announced a significant restructuring of their existing collaboration into a new licensing agreement that will enable both companies to prioritize their investments and streamline their respective mRNA development efforts. Since 2020, GSK and CureVac have been collaborating on the development of mRNA vaccines aimed at addressing infectious diseases. This partnership has led to the advancement of several vaccine candidates, including those for seasonal influenza and COVID-19, which are currently in Phase 2 clinical trials, as well as a candidate for avian influenza in Phase 1 development. All of these candidates utilize CureVac’s proprietary second-generation...https://lnkd.in/dekPE_PG

A deeper look into GSK's discontinuation of its herpes simplex virus (HSV), leaving a significant gap in the market. With the rise of global genital herpes cases and an ongoing unmet need for both prophylactic and therapeutic vaccines. Now, Moderna and BioNTech SE are set to have an unrivalled impact in their respective markets, potentially changing the HSV vaccine landscape. Click to read more. #globaldata #mRNA #Vaccines #Pharma #Herpes #Healthcare #Biotech

🌟 Inverse Vaccines: a novel strategy to treat Autoimmune Diseases 🔬 What are Inverse Vaccines? Inverse vaccines are immune tolerance therapies for autoimmune diseases. In other words, they train the immune system to stop attacking specific autoimmune disease-associated antigens. 💪 Benefits for Patients Reduced Side Effects: They do not make patients more susceptible to infections as traditional immunosuppressive drugs do. Applicability: They hold the potential for treating several autoimmune diseases whose disease-associated antigen is well known. Clinical Trials: Promising animal studies are currently being translated into human clinical trials, with several start-ups and pharmaceutical companies already established in the field. 🥁 Stay tuned for more updates on this exciting topic! https://lnkd.in/d9SWTx4D #AutoimmuneDiseases #InverseVaccines #Innovation #Healthcare #Alcimed

GSK and CureVac have announced they have entered into a new licensing agreement worth over €1.4bn to restructure their current collaboration to develop mRNA vaccines for infectious diseases.   The new deal will allow both companies to prioritise investment and focus on their respective mRNA development activities.   Since 2020, the companies have been working together to develop mRNA vaccines for infectious diseases, including vaccine candidates for seasonal influenza and COVID-19, utilising CureVac’s proprietary second-generation mRNA backbone.   Under the terms of the new agreement, GSK will gain full control of developing and manufacturing candidate vaccines and will have worldwide rights to commercialise them, while CureVac will retain exclusive rights to the addition of undisclosed and preclinically validated infectious disease targets from the prior collaboration, with the freedom to independently develop and partner mRNA vaccines in any other infectious disease or other indication.   CureVac will receive an upfront payment of €400m in addition to a further €1.05bn in development, regulatory and sales milestones, plus tiered royalties, which will replace all previous financial agreements from the prior collaboration agreement between both companies.   Commenting on the new agreement, GSK’s chief scientific officer, Tony Wood, commented: “With this new agreement, we will apply GSK’s capabilities, partnerships and intellectual property to CureVac’s technology to deliver these promising vaccines at pace.”   Alexander Zehnder, chief executive officer, CureVac, said: “This new licensing agreement puts us in a strong financial position and enables us to focus on efforts [to build] a strong research and development pipeline.” Read more: https://lnkd.in/eiE85DeU If you are seeking LinkedIn groups that best match your requirements, you can find an A-Z list of LinkedIn groups covering pharmaceutical, medical and life science groups here:  https://bit.ly/4caKquL

“The process of producing the vaccine itself defines the product.” An interesting commentary by Barry C Buckland (Merck Research Laboratories) highlights most important aspects of vaccine development. A good read for vaccine CMC team. https://lnkd.in/gz8msQ9m Vaccines are difficult to characterize which requires initial development of advanced analytical methods for characterization very early in process development to demonstrate equivalence during process changes during development lifecycle. The same stands true for potency assays. “The analytics need to be sufficiently well developed so that the precise definition of potency at a particular point in the development cycle will not change as the program progresses. Specifically, it is essential to be able to link the clinical performance, comparing the vaccine made at an early-stage development and testing in the clinic”. In important requirement of potency assay is its ability to monitor stability of the final product. In addition to demonstrate clinical performance of the product a robust serological assay lays the foundation. The commentary illustrates development of HPV, Rotavirus and Vericella zoster vaccines.

#Vaccines #technologies - Global Industry to Generate Revenue at a CAGR of 4.0% by 2029 𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝒕𝒉𝒆 𝑷𝑫𝑭 𝑩𝒓𝒐𝒄𝒉𝒖𝒓𝒆 𝒕𝒐 𝑮𝒂𝒊𝒏 𝑴𝒐𝒓𝒆 𝑰𝒏𝒔𝒊𝒈𝒉𝒕𝒔: https://lnkd.in/d7gSHytq The size of global vaccines market (including COVID-19 vaccines) in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029. Similarly The global vaccines market (excluding COVID-19 vaccines) in terms of revenue was estimated to be worth $53.0 billion in 2024 and is poised to reach $80.3 billion by 2029, growing at a CAGR of 8.7% from 2024 to 2029. --> 𝑫𝒓𝒊𝒗𝒆𝒓: 𝑭𝒐𝒄𝒖𝒔 𝒐𝒏 𝒗𝒂𝒄𝒄𝒊𝒏𝒆 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 𝒂𝒏𝒅 𝒍𝒂𝒖𝒏𝒄𝒉𝒆𝒔 --> 𝑹𝒆𝒔𝒕𝒓𝒂𝒊𝒏𝒕: 𝑯𝒊𝒈𝒉 𝒄𝒐𝒔𝒕 𝒐𝒇 𝒗𝒂𝒄𝒄𝒊𝒏𝒆 𝒅𝒆𝒗𝒆𝒍𝒐𝒑𝒎𝒆𝒏𝒕 --> 𝑶𝒑𝒑𝒐𝒓𝒕𝒖𝒏𝒊𝒕𝒚: 𝑹𝒊𝒔𝒊𝒏𝒈 𝒇𝒐𝒄𝒖𝒔 𝒐𝒏 𝒕𝒉𝒆𝒓𝒂𝒑𝒆𝒖𝒕𝒊𝒄 𝒗𝒂𝒄𝒄𝒊𝒏𝒆𝒔 --> 𝑪𝒉𝒂𝒍𝒍𝒆𝒏𝒈𝒆: 𝑺𝒕𝒓𝒊𝒏𝒈𝒆𝒏𝒕 𝑹𝒆𝒈𝒖𝒍𝒂𝒕𝒐𝒓𝒚 𝑷𝒓𝒐𝒄𝒆𝒔𝒔𝒆𝒔 Key Players: Moderna BioNTech SE Novavax CureVac INOVIO Pharmaceuticals, Inc. Clover Biopharmaceuticals Dynavax Technologies VBI Vaccines Inc. Imvax, Inc. Emergent BioSolutions Bharat Biotech Zydus Group Serum Institute of India Pvt. Ltd. Anges MG, Inc Nexvet Biopharma, now part of Zoetis Mitsubishi Tanabe Pharma America iBio, Inc. GeoVax Labs, Inc. Arcturus Therapeutics Altimmune, Inc. Vaxart, Inc. Sanaria Inc. Valneva REITHERA 𝐑𝐞𝐜𝐞𝐧𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐨𝐟 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲: In April 2024, Bharat Biotech and Bilthoven Biologicals entered into a collaboration to produce and supply oral polio vaccines. In April 2024, VBI Vaccines Inc. expanded its stratergic collaboration with Government of Canada to accelerate development proprietary MLE platform, enveloped virus-like particle vaccine technology that enables the coding of eVLPs using mRNA. In January 2024, Indian Immunologicals Limited (IIL), launched India’s ‘first’ indigenously developed Hepatitis A vaccine, Havisure. In August 2023, Pfizer Inc., received US FDA approval for ABRYSVO (Respiratory Syncytial Virus Vaccine) for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. In May 2023, GSK plc, received US FDA approval for Arexvy (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.

𝗩𝗮𝗰𝗰𝗶𝗻𝗲𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗴𝗿𝗼𝘄 𝗮𝘁 𝗮 4.0% 𝗖𝗔𝗚𝗥 𝗳𝗿𝗼𝗺 2024 𝘁𝗼 2029 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗙𝗿𝗲𝗲 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁-https://lnkd.in/gzqjFKmP The size of global vaccines market (including COVID-19 vaccines) in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029. Similarly The global vaccines market (excluding COVID-19 vaccines) in terms of revenue was estimated to be worth $53.0 billion in 2024 and is poised to reach $80.3 billion by 2029, growing at a CAGR of 8.7% from 2024 to 2029. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 Vaccines Europe CZ Vaccines  AJ Vaccines AchilleS Vaccines      Institute of Virology, Vaccines and Sera “Torlak” Emergex Vaccines Sanofi GSK Novartis   Merial Neon Therapeutics  Ceva Santé Animale   HIPRA     Bavarian Nordic CureVac Valneva FARMAINDUSTRIA Chiltern ROVI Pharma Industrial Services   MSD Switzerland MSD in the UK BIOASTER APIFARMA - Portuguese Pharmaceutical Industry Association     iBET - Instituto de Biologia Experimental e Tecnológica Paul-Ehrlich-Institut Touchlight Theorem (now Chiltern) Vienna BioCenter Batavia Biosciences Genedata Huvepharma nv Allergy Therapeutics Laboratorios Syva MSD Belgium The Pirbright Institute GenIbet Biopharmaceuticals Evaxion Biotech A/S FUJIFILM Diosynth Biotechnologies Morgan Advanced Materials Barinthus Biotherapeutics

In the current issue of Vaccines MDPI, newly published preclinical non-human primate data demonstrates the potential of Vaxart’s COVID-19 vaccine candidates to protect against multiple SARS-CoV-2 variants of concern. Read more about the key findings from this study in our press release here: https://bitly.ws/3cqh3 #pillthatmovestheneedle

💻 Now's the time to register for our upcoming webinar on Next-Generation Rapid mRNA Vaccine CQA Analytics with bioMérieux 👉 Join this webinar to learn how InDevR and their VaxArray multiplexed immunoassay platform empower Critical Quality Attribute (CQA) testing for multivalent mRNA vaccines. 📱 This presentation will focus on key applications of the microarray-based, multiplexed VaxArray platform in vaccine analytics, with a focus on how the technology can be effectively utilised throughout the development and clinical validation of multivalent mRNA vaccines. 📱 Using influenza mRNA vaccines as a case study, we present data from a variety of on market and in development VaxArray assays to highlight how the platform empowers cost-effective analytical development throughout mRNA vaccine product lifecycle. You'll be able to ask our speaker Dr Erica Dawson questions too! Register now: https://bit.ly/3HiIm5u #Vaccines #Webinar #Assay